Archived Press Releases







10.25.05

MonoSol RX, LLC announced today that it has initiated the DEA Registration of its Tennessee development facility and its Indiana manufacturing facility for Class II-V scheduled drugs

PORTAGE, Ind., Aug. 24 /PRNewswire/ — MonoSolRx, LLC announced today that it has initiated the DEA Registration of its Tennessee development facility and its Indiana manufacturing facility for Class II-V scheduled drugs. MonoSolRx is working with an undisclosed DEA consultant to help effect the registration.

MonoSolRx's CEO P. Scott Bening commented: "This registration was required by increasing demand from pharmaceutical companies interested in scheduled drugs, including the pain category, to be placed in quick-dissolving film for oral delivery. Quick dissolving film enables dose administration for individuals who are compromised by severe pain and have difficulty swallowing conventional tablets."

MonoSolRx's Vice President of Operations Dr. Tushar Misra said: "The ability to handle controlled substances will greatly enhance our ability to work with our many clients who have asked us to use scheduled drug ingredients in our film dosage form. The ability to work with scheduled drugs, complemented by our work with higher loading films and controlled release delivery in film, strengthens our offering."

About MonoSolRx LLC [www.monosolrx.com]
MonoSolRx LLC is headquartered in Portage, Indiana. MonoSolRx is a leading drug delivery company that uses film as a fast-dissolve oral drug delivery platform. MonoSolRx previously acquired substantially all of the assets of Kosmos Pharma, including its extensive oral film intellectual property portfolio. MonoSolRx's FDTAB film oral dosage form looks like a postage stamp and dissolves readily on the tongue to deliver drugs to a patient, replacing the use of conventional tablets and capsules. MonoSolRx also employs its proprietary film technology on a range of veterinary and nutraceutical products.

Source: Monosol RX